Tags · Evidence
randomised trial
Randomised controlled trial evidence.
Related in this group: STEP programme · SURMOUNT programme · SURPASS programme · SELECT trial · FLOW trial · SOUL trial · TRIUMPH programme · PIONEER programme · SUSTAIN programme · LEADER trial · meta-analysis · observational data
174 topics · page 3 of 6
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
[2026 update] Amylin and gastric emptying: overlapping mechanisms with incretins
Amylin and gastric emptying: overlapping mechanisms with incretins — setting out what I have, and where I think it stops being reliable. Session topic: FLOW ( N Engl J Med , 2024). Please read it before…
|
+21 | 25 | 44k | 5mo |
|
Why semaglutide's albumin binding is the whole reason weekly dosing works
Asking directly, because I could not find a straight answer: Why semaglutide's albumin binding is the whole reason weekly dosing works Session topic: SELECT ( N Engl J Med , 2023). Please read it before…
|
2 | 63k | 5mo | |
|
Reading SURMOUNT-1 without the press release — one year on
Reading SURMOUNT-1 without the press release — one year on — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a claim I do not…
|
+45 | 50 | 7.6k | 5mo |
|
Coming back to: The SOUL trial and oral semaglutide cardiovascular outcomes
The SOUL trial and oral semaglutide cardiovascular outcomes — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a claim I do not…
|
+100 | 104 | 4.2k | 5mo |
|
Non-inferiority margins: how they are chosen and how they are abused — a second dataset
Non-inferiority margins: how they are chosen and how they are abused — a second dataset — setting out what I have, and where I think it stops being reliable. Comparing FLOW ( N Engl J Med , 2024) with…
|
+32 | 37 | 574 | 5mo |
|
Revisiting: What SELECT changed about how semaglutide is discussed, and what it did not
Revisiting: What SELECT changed about how semaglutide is discussed, and what it did not Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J…
|
2 | 1.9k | 5mo | |
|
[2026 update] Reading a supplementary appendix and finding the interesting part
On the subject in the title: Reading a supplementary appendix and finding the interesting part Working notes rather than a conclusion. Comparing SELECT ( N Engl J Med , 2023) with FLOW ( N Engl J Med , 2024)…
|
+39 | 44 | 8.2k | 5mo |
|
Journal club: semaglutide in MASH, and surrogate endpoints — does this still hold?
Journal club: semaglutide in MASH, and surrogate endpoints — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing STEP 1 ( N Engl J Med ,…
|
3 | 28k | 6mo | |
|
Sample size calculations, read backwards from the published number
Sample size calculations, read backwards from the published number Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SUSTAIN 6 ( N Engl J Med , 2016). Please…
|
2 | 8.1k | 6mo | |
|
Second pass at: Why semaglutide's albumin binding is the whole reason weekly dosing works
Second pass at: Why semaglutide's albumin binding is the whole reason weekly dosing works Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet ,…
|
2 | 39k | 6mo | |
|
How to read a phase 2 result without treating it as a phase 3 result — what changed since
Asking directly, because I could not find a straight answer: How to read a phase 2 result without treating it as a phase 3 result — what changed since Session topic: STEP 2 ( Lancet , 2021). Please read it…
|
+25 | 35 | 568 | 6mo |
|
Why oral semaglutide needs an absorption enhancer at all
Why oral semaglutide needs an absorption enhancer at all I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen STEP 1 ( N Engl J Med , 2021) cited in support of…
|
+59 | 65 | 61k | 7mo |
|
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing SURPASS-4 ( Lancet , 2021)…
|
+130 | 135 | 11k | 7mo |
|
The 2.5 mg starting dose is not a therapeutic dose — why that matters — a second dataset
Posting this under the heading it deserves: The 2.5 mg starting dose is not a therapeutic dose — why that matters — a second dataset Everything below is what sits behind that. Session topic: STEP 8 ( JAMA ,…
|
+12 | 16 | 11k | 7mo |
|
How to read a forest plot, properly, from scratch
The question in the title: How to read a forest plot, properly, from scratch I will give what I have already checked below so nobody repeats it. Session topic: STEP 4 ( JAMA , 2021). Please read it before…
|
+73 | 81 | 17k | 7mo |
|
Retatrutide's phase 2 heart-rate signal and how to think about it
On the subject in the title: Retatrutide's phase 2 heart-rate signal and how to think about it Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a claim…
|
+19 | 23 | 20k | 7mo |
|
How to read a phase 2 result without treating it as a phase 3 result
The question in the title: How to read a phase 2 result without treating it as a phase 3 result I will give what I have already checked below so nobody repeats it. Session topic: FLOW ( N Engl J Med , 2024).…
|
+36 | 40 | 35k | 7mo |
|
Journal club: the retatrutide phase 2 obesity paper
Journal club: the retatrutide phase 2 obesity paper — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think it…
|
+7 | 11 | 33k | 7mo |
|
Reading SURMOUNT-1 without the press release
Posting this under the heading it deserves: Reading SURMOUNT-1 without the press release Everything below is what sits behind that. I have seen SURMOUNT-4 ( JAMA , 2024) cited in support of a claim I do not…
|
+103 | 121 | 7k | 7mo |
|
Second pass at: Cagrilintide's dosing interval and the pharmacokinetics behind it
On the subject in the title: Second pass at: Cagrilintide's dosing interval and the pharmacokinetics behind it Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please…
|
+2 | 6 | 2.4k | 7mo |
|
Amylin analogue mechanism: satiety signalling separate from GLP-1 — does this still hold?
Amylin analogue mechanism: satiety signalling separate from GLP-1 — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4 (…
|
+21 | 25 | 45k | 7mo |
|
Why tirzepatide titration schedules have more steps than semaglutide's
Asking directly, because I could not find a straight answer: Why tirzepatide titration schedules have more steps than semaglutide's Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…
|
4 | 8.4k | 7mo | |
|
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version
On the subject in the title: Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med ,…
|
+85 | 90 | 13k | 7mo |
|
Tirzepatide's shorter half-life and its one practical consequence
On the subject in the title: Tirzepatide's shorter half-life and its one practical consequence Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a claim I…
|
+18 | 29 | 20k | 8mo |
|
Journal club: how we handle discontinuation in obesity trials — what changed since
Journal club: how we handle discontinuation in obesity trials — what changed since — setting out what I have, and where I think it stops being reliable. Session topic: STEP 4 ( JAMA , 2021). Please read it…
|
+14 | 18 | 35k | 8mo |
|
Oral versus injectable exposure: comparing apples to a different fruit
Oral versus injectable exposure: comparing apples to a different fruit — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with SURMOUNT-4 ( JAMA ,…
|
+19 | 23 | 332 | 8mo |
|
Follow-up: Retatrutide phase 2 in type 2 diabetes: the Lancet paper
Retatrutide phase 2 in type 2 diabetes: the Lancet paper Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I…
|
+1 | 5 | 31k | 8mo |
|
Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA
Posting this under the heading it deserves: Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA Everything below is what sits behind that. I have seen SCALE ( N Engl J Med , 2015) cited in support…
|
+4 | 8 | 14k | 8mo |
|
Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's
Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med ,…
|
+89 | 101 | 32k | 8mo |
|
Tirzepatide and nausea: is the profile genuinely different or just differently reported?
Asking directly, because I could not find a straight answer: Tirzepatide and nausea: is the profile genuinely different or just differently reported? Comparing PIONEER 6 ( N Engl J Med , 2019) with STEP 8 (…
|
+18 | 22 | 37k | 8mo |